Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma.

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Metabolic Bone Disease and Related Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0221-8747(82)90013-3PMID 6218370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatitein vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats

  2005cited by this paper
• Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor.

  1981cited by this paper
• Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue.

  1980cited by this paper
• Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

  1980cited by this paper
• Treatment of severe hypecalcaemia with calcitonin

  1980cited by this paper
• Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.

  1980cited by this paper
• Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone.

  1980cited by this paper
• Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.

  1980cited by this paper
• Effect of sodium fluoride, calcium carbonate, and vitamin D on the skeleton in multiple myeloma

  1980cited by this paper
• Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.

  1980cited by this paper
• Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.

  1979cited by this paper
• Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.

  1977cited by this paper
• Treatment of osteolytic myelomatosis with mithramycin.

  1975cited by this paper
• Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo.

  1975cited by this paper
• Evidence for the secretion of an osteoclast stimulating factor in myeloma.

  1974cited by this paper
• Ineffectiveness of fluoride therapy in multiple myeloma.

  1972cited by this paper
• Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo

  1969cited by this paper
• Diphosphonates Inhibit Formation of Calcium Phosphate Crystals in vitro and Pathological Calcification in vivo

  1969cited by this paper

• Efficacy of Bone-Modifying Agents in Preventing Vertebral Complications of Multiple Myeloma: A Systematic Review and Meta-Analysis.

  2025cites this paper
• A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives

  2022cites this paper
• Clodronate.

  2020cites this paper
• [Osteoprotective therapy with bisphosphonates or denosumab in patients with multiple myeloma: benefit and risks].

  2018cites this paper
• Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project

  2017cites this paper
• Bisphosphonates in multiple myeloma: an updated network meta-analysis.

  2017cites this paper
• expert committee of the Spanish Myeloma Group from the PETHEMA group

  2016cites this paper
• Indirect Treatment Comparison

  2014cites this paper
• Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis

  2014cites this paper
• Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.

  2013cites this paper
• Bisphosphonates in multiple myeloma: a network meta-analysis.

  2012cites this paper
• The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma

  2012cites this paper
• A Canadian Perspective on the Use of Bisphosphonates in the Clinical Management of Multiple Myeloma

  2011cites this paper
• Bisphosphonates in multiple myeloma.

  2010cites this paper
• [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].

  2010cites this paper
• The Stata Journal

  2010cites this paper
• Meta-Analysis in context: Chemotherapy versus Chemotherapy combined with Bisphosphonate Therapy in Multiple Myeloma Patients

  2009cites this paper
• Clodronate treatment in patients with malignancy-associated hypercalcemia.

  2009cites this paper
• Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.

  2009cites this paper
• Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.

  2009cites this paper
• Bone turnover markers: an appreciation of the contribution of Dr. P.D. Delmas.

  2008cites this paper
• Clodronate in hypercalcemia of malignancy

  2007cites this paper
• CHAPTER 25 – Bisphosphonates

  2006cites this paper
• Myeloma bone disease.

  2005cites this paper
• Rationale for the use of clodronate in osteoporosis

  2005cites this paper
• A systematic review of the role of bisphosphonates in metastatic disease.

  2004cites this paper
• Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study

  2004cites this paper
• Management of bone disease

  2004cites this paper
• Mechanism of action of bisphosphonates

  2003cites this paper
• Treatment of multiple myeloma.

  2003cites this paper
• Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.

  2003cites this paper
• Traitement du myélome multiple

  2003cites this paper
• Bisphosphonate therapy in the oncology setting

  2003cites this paper
• Child psychiatric disorder and relative age within school year: cross sectional survey of large population sample

  2003cites this paper
• Effect of Cyclical Intravenous Clodronate Therapy on Bone Mineral Density and Markers of Bone Turnover in Patients Receiving Home Parenteral Nutrition

  2003cites this paper
• American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

  2002cites this paper
• Osteoporosi: la malattia e il suo costo sanitario

  2002cites this paper
• Bisphosphonates for the relief of pain secondary to bone metastases.

  2002cites this paper
• Bisphosphonate therapy in multiple myeloma: past, present, future

  2002cites this paper
• Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.

  2002cites this paper
• Bisphosphonates in multiple myeloma.

  2002cites this paper
• Diagnosis and management of multiple myeloma.

  2001cites this paper
• CHAPTER 45 – Acute Management of Hypercalcemia

  2001cites this paper
• Bone mineral density in multiple myeloma patients after intravenous clodronate therapy.

  2001cites this paper
• Diagnosis and management of multiple myeloma

  2001cites this paper
• Osteoporosis Secondary to Illnesses and Medications

  2001cites this paper
• Strategies for Management of Prostate Cancer-Related Bone Pain

  2001cites this paper
• Bone disease in myeloma

  2001cites this paper
• Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis.

  2001cites this paper
• 3.3 – Osteolytic tumor-induced bone disease

  2000cites this paper
• Oral bisphosphonates

  2000cites this paper
• Bisphosphonates in multiple myeloma

  2000cites this paper
• Bisphosphonates in multiple myeloma.

  1999cites this paper
• Treatment of multiple myeloma.

  1999cites this paper
• [Action of bisphosphonates on malignant osteolysis].

  1999cites this paper
• [Standard treatment of multiple myeloma].

  1999cites this paper
• Use of Bisphosphonates in the Treatment of Multiple Myeloma.

  1998cites this paper
• BONE DISEASE IN MULTIPLE MYELOMA

  1998cites this paper
• The role of bisphosphonates for the treatment of bone disease in multiple myeloma.

  1998cites this paper
• Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

  1998cites this paper
• Mechanisms of action of bisphosphonates.

  1998cites this paper
• Tumorinduzierte Hyperkalzämie – Diagnostik und Therapie

  1997cites this paper
• Clodronate

  1997cites this paper
• Traitement conventionnel du myélome multiple

  1997cites this paper
• Pathogenesis and management of bone lesions in multiple myeloma.

  1997cites this paper
• Towards better pain treatment in cancer.

  1996cites this paper
• Bioavailability of two clodronate formulations.

  1996cites this paper
• Adverse Effects of Bisphosphonates

  1996cites this paper
• [Multiple myeloma and bone manifestations. Role of clodronate].

  1996cites this paper
• Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer.

  1996cites this paper
• Bisphosphonates in multiple myeloma: current status; future perspectives.

  1996cites this paper
• [Recommendations for a successful cancer pain management in adults and children].

  1996cites this paper
• Bisphosphonates and the Treatment of Bone Disease in the Elderly

  1996cites this paper
• Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy--a pilot study of the German Myeloma Treatment Group (GMTG).

  1996cites this paper
• Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma

  1996cites this paper
• Causes and Treatment of Bone Pain of Malignant Origin

  1996cites this paper
• Clodronate and osteoporosis.

  1996cites this paper
• Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

  1996cites this paper
• Increasing bone density in myeloma patients after the administration of clodronate.

  1995cites this paper
• Use of clodronate in multiple myeloma.

  1995cites this paper
• The mechanisms of bone lesions in human plasmacytomas.

  1995cites this paper
• [Role of bisphosphonates in the treatment of tumoral osteolysis].

  1995cites this paper
• Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy.

  1995cites this paper
• Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.

  1995cites this paper
• Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma.

  1994cites this paper
• A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma.

  1994cites this paper
• Consequences of neoplasia induced bone-resorption and the use of clodronate (review).

  1994cites this paper
• Clodronate

  1994cites this paper
• Metastatic Bone Disease

  1994cites this paper
• [Bone manifestations of multiple myeloma and therapeutic possibilities].

  1994cites this paper
• Bisphosphonates: Mechanisms of Actionand Clinical Use in Hypercalcemia of Malignancy and Tumor-Induced Bone Destruction

  1994cites this paper
• Morphological Findings in Bone Metastasis, Tumorosteopathy and Antiosteolytic Therapy

  1994cites this paper
• Subgroup and cost‐benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma

  1994cites this paper
• Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal Impairment

  1994cites this paper
• [Biphosphonates and multiple myeloma].

  1993cites this paper
• Lack of variation of plasma beta-endorphin after clodronate infusion in patients with increased bone resorption

  1993cites this paper
• Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study.

  1993cites this paper
• [The use of the preparation bonefos in the combined therapy of multiple myeloma patients].

  1993cites this paper
• New bisphosphonates in the treatment of bone metastases

  1993cites this paper
• Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications

  1993cites this paper